Is Ozempic the only GLP-1 approved for lowering chronic kidney disease risk?
No. Ozempic (semaglutide) is one GLP-1 receptor agonist with kidney-risk-reduction evidence, but it is not the only one in this class.
GLP-1 therapies have been studied for kidney outcomes, and multiple agents have evidence supporting slower progression of diabetic kidney disease and reduced renal events in relevant patient groups. Ozempic is often highlighted because its kidney benefit is well established in large outcomes trials, but the broader class includes other GLP-1 drugs with similar evidence.
Which other GLP-1 drugs have evidence for kidney outcomes?
Other GLP-1 receptor agonists (including liraglutide and dulaglutide) have also shown improvements in kidney-related outcomes in people with type 2 diabetes and higher cardiovascular risk, depending on the specific trial endpoints and patient characteristics.
That means Ozempic is not uniquely positioned as the only GLP-1 with approved/clinically recognized kidney-risk reduction.
Does “approved” mean the same thing for every GLP-1 (kidney claims vs trial evidence)?
Not exactly. “Approved to lower the risk of chronic kidney disease” can depend on:
- Which regulator (FDA/EMA, etc.) issued the approval
- Whether the label includes a kidney-specific indication or wording
- The exact renal endpoints used (for example, onset/worsening of kidney disease, eGFR decline, albuminuria, need for dialysis)
So a GLP-1 may have strong trial evidence for kidney benefit without having the exact same regulatory label phrasing as Ozempic.
What to check to confirm a specific product’s kidney-risk approval
If you want to verify whether a particular GLP-1 is approved for kidney-risk reduction in your country, check the drug’s:
- Prescribing information label (indications section)
- Wording tied to chronic kidney disease or diabetic kidney disease risk reduction
- Eligibility (for example, type 2 diabetes with established cardiovascular disease or specific CKD stages)
If you tell me your country, I can answer more precisely
Regulatory approvals vary by country. If you share whether you mean the FDA (U.S.) or another regulator, I can narrow the answer to the specific GLP-1 labels that include kidney-risk reduction language.